Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo and Active Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Potential Efficacy of a 12-Week Treatment With YM543 in Subjects With Type 2 Diabetes Mellitus

NCT00454233 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00454233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00454233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo and Active Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Potential Efficacy of a 12-Week Treatment With YM543 in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
June 30, 2008
Enrollment
97 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2